688020-78-2

Basic information

• Product Name: 5,6,7,8-tetrahydro-4H-thiazolo-[4,5-d]-azepin-2-ylamine hydrobromide
• Synonyms: 5,6,7,8-tetrahydro-4H-thiazolo-[4,5-d]-azepin-2-ylamine hydrobromide;5,6,7,8-TETRAHYDRO-4H-THIAZOLO-[4,5-D]-AZEPIN-2-YLAMINE HBR
• CAS NO: 688020-78-2
• Molecular Formula: BrH*C₇H₁₁N₃S
• Molecular Weight: 250.15928
• EINECS: -0
• Mol File: 688020-78-2.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 5,6,7,8-tetrahydro-4H-thiazolo-[4,5-d]-azepin-2-ylamine hydrobromide(CAS DataBase Reference)
• NIST Chemistry Reference: 5,6,7,8-tetrahydro-4H-thiazolo-[4,5-d]-azepin-2-ylamine hydrobromide(688020-78-2)
• EPA Substance Registry System: 5,6,7,8-tetrahydro-4H-thiazolo-[4,5-d]-azepin-2-ylamine hydrobromide(688020-78-2)

Safety Data

• Hazardous Substances Data: 688020-78-2(Hazardous Substances Data)

Upstream product

• 50492-22-3 azepan-4-one hydrochloride 
• 17356-08-0 thiourea 

Relevant articles and documents

FUSED GLYCOSIDASE INHIBITORS

Compounds of formula (I), wherein A, Z, E, R1, R2, m and n have the meaning according to the claims can be employed, inter alia, for the treatment of tauopathies and Alzheimer's disease.

4-ARYL IMIDAZOLE DERIVATIVES AS MGLUR5 POSITIVE ALLOSTERIC MODULATORS

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

1,2,4 -TRIAZOLES AS ALLOSTERIC MODULATORS OF MGLU5 RECEPTOR ACTIVITY FOR THE TREATMENT OF SCHIZOPHRENIA OF DEMENTIA

This invention relates to compounds of formula (I) their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

4-ARYL IMIDAZOLE DERIVATIVES AS MGLU5 POSITIVE ALLESTERIC MODIULATORS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurologic

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.

NOVEL COMPOUNDS

This invention relates to compounds of formula I their use as positive allosteric modulators of mGlu5 receptor activity, pharmaceutical compositions containing the same, and methods of using the same as agents for treatment and/or prevention of neurological and psychiatric disorders associated with glutamate dysfunction such as schizophrenia or cognitive decline such as dementia or cognitive impairment. A, B, X, R1, R2, R3 have meanings given in the description.